Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
The wearable combines AI and neurotechnology to modulate the nervous system to help alleviate functional limitations caused by tremors. The company's AI continuously adjusts stimulation parameters to provide therapy that calms tremors and helps restore motor control.
Read more here.
A technology-driven overhaul of the NHS could add £40bn a year to the UK economy and increase healthy life expectancy for millions, a new report suggests.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us